Gilead's Veklury Study Shows Faster COVID-19 Recovery, Reduced Disease Progression, MortalityBenzinga • 10/09/20
Gilead CEO: 'We have ample supply' of remdesivir for hospitalized coronavirus patientsCNBC • 10/09/20
Final Results of National Institute of Allergy and Infectious Diseases’ ACTT-1 Trial Published in New England Journal of Medicine Expand Clinical Benefits of Veklury® (remdesivir) for the Treatment of COVID-19Business Wire • 10/08/20
Covid Report: Regeneron Pharmaceuticals Files For Emergency Authorization; Gilead Inks European Supply DealInvestors Business Daily • 10/08/20
Gilead Sciences Signs Joint Procurement Agreement With the European Commission for Veklury® (remdesivir)Business Wire • 10/08/20
Regeneron Pharmaceuticals, Gilead Sciences Shares Rise As Their Therapies Used To Treat PresidentInvestors Business Daily • 10/05/20
Gilead, Regeneron, Amgen: Covid Treatment Stocks Still Worth Looking At As Vaccine Nears?Forbes • 10/02/20
Gilead Sciences Update on Supply and Distribution of Veklury® (remdesivir) in the United StatesBusiness Wire • 10/01/20
Gilead Sciences Presents Data From HIV Research and Development Programs at HIV Glasgow 2020Business Wire • 09/30/20
The Zacks Analyst Blog Highlights: Anheuser-Busch InBev, Gilead Sciences, Canadian National Railway, Stryker Corp and Goldman SachsZacks Investment Research • 09/28/20
European Commission Grants Marketing Authorization for Jyseleca® ▼ (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid ArthritisBusiness Wire • 09/25/20